FiercePharma News

Latest articles

ESMO: Merck's Keytruda pushes for 2nd esophageal cancer nod with first-line survival win

ESMO: Merck's Keytruda pushes for 2nd esophageal cancer nod with first-line survival win chelfand Mon, 09/21/2020 - 12:25

FiercePharmaPolitics—White House, pharma pricing talks fell apart over demand for 'Trump Cards': NYT

FiercePharmaPolitics—White House, pharma pricing talks fell apart over demand for 'Trump Cards': NYT esagonowsky Mon, 09/21/2020 - 09:51

ESMO: Roche, after Tecentriq's ovarian cancer fail, banks hopes on final survival analysis

ESMO: Roche, after Tecentriq's ovarian cancer fail, banks hopes on final survival analysis aliu Sun, 09/20/2020 - 07:45

Chinese customs raids J&J CAR-T partner Legend's office, puts new CEO under 'residential surveillance'

Chinese customs raids J&J CAR-T partner Legend's office, puts new CEO under 'residential surveillance' aliu Mon, 09/21/2020 - 09:55

ESMO: Merck's Keytruda doubles 5-year survival rate for lung cancer patients

ESMO: Merck's Keytruda doubles 5-year survival rate for lung cancer patients chelfand Mon, 09/21/2020 - 02:00

ESMO: Regeneron and Sanofi gun for Libtayo in first-line NSCLC with fresh survival stats

ESMO: Regeneron and Sanofi gun for Libtayo in first-line NSCLC with fresh survival stats arlene.weintraub Fri, 09/18/2020 - 09:31

ESMO: Lilly's Verzenio pressures Pfizer with practice-changing win in early breast cancer

ESMO: Lilly's Verzenio pressures Pfizer with practice-changing win in early breast cancer aliu Fri, 09/18/2020 - 10:13

ESMO: AstraZeneca's targeted lung cancer med Tagrisso slashes CNS recurrence by 82%

ESMO: AstraZeneca's targeted lung cancer med Tagrisso slashes CNS recurrence by 82% chelfand Thu, 09/17/2020 - 19:23

ESMO: New Trodelvy breast, bladder cancer data show why Gilead's going big for Immunomedics

ESMO: New Trodelvy breast, bladder cancer data show why Gilead's going big for Immunomedics aliu Sat, 09/19/2020 - 08:14

ESMO: Roche's mixed results put Tecentriq's triple-negative breast cancer use into question

ESMO: Roche's mixed results put Tecentriq's triple-negative breast cancer use into question aliu Fri, 09/18/2020 - 12:53

Discover, share and read the best on the web

Subscribe to RSS Feeds, Blogs, Podcasts, Twitter searches, Facebook pages, even Email Newsletters! Get unfiltered news feeds or filter them to your liking.

Get Inoreader
Inoreader - Subscribe to RSS Feeds, Blogs, Podcasts, Twitter searches, Facebook pages, even Email Newsletters!